Christopher J Kochansky - JoVE Visualize

Showing results (1-10 of 16) with videos related to

Pageof 2

Sort By:

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 9, 2006

The role of P-glycoprotein in the bioactivation of raloxifeneJae H Chang, Christopher J Kochansky, Magang Shou

Lipids|December 29, 2018

Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle ToxicityChristopher J Kochansky, Michael J Lyman, Scott E Fauty, et al.

Analytical Chemistry|April 15, 2005

Increasing the efficiency of in-capillary electrophoretically mediated microanalysis reactions via rapid polarity switchingBrandi D Sanders, Rachel L Slotcavage, Diana L Scheerbaum, et al.

Canadian Journal of Physiology and Pharmacology|June 26, 2019

Decreased liver triglyceride content in adult rats exposed to protein restriction during gestation and lactation: roles of hepatic lipogenesis and lipid utilization in muscle and adipose tissueClaudia Mendez-Garcia, Afsana Trini, Veron Browne, et al.

Molecular Pharmaceutics|March 19, 2008

Impact of pH on plasma protein binding in equilibrium dialysisChristopher J Kochansky, Daniel R McMasters, Ping Lu, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004

Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker ratsMi-Sook Kim, Sui Wang, Zhongzhou Shen, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 27, 2005

Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronideChristopher J Kochansky, Yuan-Qing Xia, Sui Wang, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2004

Identification and metabolism of a novel dihydrohydroxy-S-glutathionyl conjugate of a peroxisome proliferator-activated receptor agonist, MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], in ratsVijay Bhasker G Reddy, George A Doss, Mellissa Creighton, et al.

Rapid Communications in Mass Spectrometry : RCM|March 26, 2020

Metabolite identification using an ion mobility enhanced data-independent acquisition strategy and automated data processingTatiana Radchenko, Christopher J Kochansky, Mark Cancilla, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2006

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humansChristopher J Kochansky, Ronda K Rippley, Kerri X Yan, et al.

Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:

Pageof 2

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 9, 2006

The role of P-glycoprotein in the bioactivation of raloxifeneJae H Chang, Christopher J Kochansky, Magang Shou

Lipids|December 29, 2018

Administration of Fenofibrate Markedly Elevates Fabp3 in Rat Liver and Plasma and Confounds Its Use as a Preclinical Biomarker of Cardiac and Muscle ToxicityChristopher J Kochansky, Michael J Lyman, Scott E Fauty, et al.

Analytical Chemistry|April 15, 2005

Increasing the efficiency of in-capillary electrophoretically mediated microanalysis reactions via rapid polarity switchingBrandi D Sanders, Rachel L Slotcavage, Diana L Scheerbaum, et al.

Canadian Journal of Physiology and Pharmacology|June 26, 2019

Decreased liver triglyceride content in adult rats exposed to protein restriction during gestation and lactation: roles of hepatic lipogenesis and lipid utilization in muscle and adipose tissueClaudia Mendez-Garcia, Afsana Trini, Veron Browne, et al.

Molecular Pharmaceutics|March 19, 2008

Impact of pH on plasma protein binding in equilibrium dialysisChristopher J Kochansky, Daniel R McMasters, Ping Lu, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004

Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker ratsMi-Sook Kim, Sui Wang, Zhongzhou Shen, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 27, 2005

Species differences in the elimination of a peroxisome proliferator-activated receptor agonist highlighted by oxidative metabolism of its acyl glucuronideChristopher J Kochansky, Yuan-Qing Xia, Sui Wang, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2004

Identification and metabolism of a novel dihydrohydroxy-S-glutathionyl conjugate of a peroxisome proliferator-activated receptor agonist, MK-0767 [(+/-)-5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[(4-trifluoromethyl) phenyl]methyl]benzamide], in ratsVijay Bhasker G Reddy, George A Doss, Mellissa Creighton, et al.

Rapid Communications in Mass Spectrometry : RCM|March 26, 2020

Metabolite identification using an ion mobility enhanced data-independent acquisition strategy and automated data processingTatiana Radchenko, Christopher J Kochansky, Mark Cancilla, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 15, 2006

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humansChristopher J Kochansky, Ronda K Rippley, Kerri X Yan, et al.

Pageof 2